^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ordastobart (INBRX-106)

    i
    Other names: INBRX-106, ES102, ES-102, ES 102, INBRX106, INBRX 106
    Associations

    News

    Trials
    Company:
    Elpiscience, Inhibrx Biosci
    Drug class:
    OX40 agonist
    Related drugs:
    Associations

    News

    Trials
    3ms
    KEYNOTE A99: Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) (clinicaltrials.gov)
    P1/2, N=333, Recruiting, Inhibrx Biosciences, Inc | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: Feb 2026 --> Oct 2026
    Trial completion date • Trial primary completion date • First-in-human
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • TMB (Tumor Mutational Burden)
    |
    EGFR mutation • TMB-H • MSI-H/dMMR • ALK rearrangement
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • ordastobart (INBRX-106)
    6ms
    A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=30, Completed, Elpiscience Biopharma, Ltd. | Recruiting --> Completed | N=82 --> 30
    Trial completion • Enrollment change
    |
    PD-L1 (Programmed death ligand 1)
    |
    Loqtorzi (toripalimab-tpzi) • ordastobart (INBRX-106)
    7ms
    INBRX-106: a hexavalent OX40 agonist that drives superior antitumor responses via optimized receptor clustering. (PubMed, J Immunother Cancer)
    Our data establish hexavalent INBRX-106 as a differentiated and more potent OX40 agonist, showcasing its ability to overcome the limitations of conventional bivalent therapies by inducing superior receptor clustering and multimeric engagement. This unique clustering mechanism amplifies OX40 signaling, driving robust T-cell activation, proliferation, and effector function in preclinical and clinical settings. These findings highlight the therapeutic potential of INBRX-106 and its capacity to redefine OX40-targeted immunotherapy, providing a compelling rationale for its further clinical development in combination with checkpoint inhibitors.
    Journal
    |
    CD8 (cluster of differentiation 8) • TNFA (Tumor Necrosis Factor-Alpha)
    |
    ordastobart (INBRX-106)
    7ms
    A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=40, Recruiting, Elpiscience (Suzhou) Biopharma, Ltd. | Not yet recruiting --> Recruiting | Initiation date: Oct 2024 --> Apr 2025
    Enrollment open • Trial initiation date
    |
    Loqtorzi (toripalimab-tpzi) • ordastobart (INBRX-106)
    1year
    A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, Elpiscience (Suzhou) Biopharma, Ltd.
    New P2 trial
    |
    Loqtorzi (toripalimab-tpzi) • ordastobart (INBRX-106)
    1year
    Neoadjuvant INBRX-106 (Hexavalent OX40 Agonist) in Combination With Pembrolizumab as a Chemotherapy-sparing Regimen for Stage II TNBC (Triple Negative Breast Cancer) Patients (clinicaltrials.gov)
    P2, N=12, Recruiting, Providence Health & Services | Not yet recruiting --> Recruiting | Trial primary completion date: Jun 2026 --> Jun 2027
    Enrollment open • Trial primary completion date • Combination therapy
    |
    Keytruda (pembrolizumab) • ordastobart (INBRX-106)
    over1year
    KEYNOTE A99: Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) (clinicaltrials.gov)
    P1/2; Phase classification: P1 --> P1/2
    Combination therapy • Phase classification • Metastases
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • TMB (Tumor Mutational Burden)
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • ordastobart (INBRX-106)
    over1year
    INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC (clinicaltrials.gov)
    P2/3, N=410, Recruiting, Inhibrx, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • ordastobart (INBRX-106)
    over1year
    A Study of ES102 (OX40 Agonist) in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=18, Completed, Elpiscience Biopharma, Ltd. | Active, not recruiting --> Completed | Trial completion date: Jun 2024 --> Mar 2024
    Trial completion • Trial completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR mutation • ALK rearrangement
    |
    ordastobart (INBRX-106)
    over1year
    Neoadjuvant INBRX-106 (Hexavalent OX40 Agonist) in Combination With Pembrolizumab as a Chemotherapy-sparing Regimen for Stage II TNBC (Triple Negative Breast Cancer) Patients (clinicaltrials.gov)
    P2, N=12, Not yet recruiting, Providence Health & Services
    New P2 trial • Combination therapy
    |
    Keytruda (pembrolizumab) • ordastobart (INBRX-106)
    almost2years
    INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC (clinicaltrials.gov)
    P2/3, N=410, Not yet recruiting, Inhibrx, Inc.
    New P2/3 trial • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • ordastobart (INBRX-106)
    almost2years
    A Study of ES102 (OX40 Agonist) in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, Elpiscience Biopharma, Ltd. | Trial completion date: Mar 2024 --> Jun 2024
    Trial completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR mutation • ALK rearrangement
    |
    ordastobart (INBRX-106)